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ABSTRACT 
The objective of present research work was to develop methotrexate loaded chitosan anchored shell nanoparticles for drug delivery in breast 
cancer. Chitosan nanoparticles (CS-NPs) were synthesized by ionic gelation of chitosan using sodium tripolyphosphate (STPP). The optimized 
nanoparticles were characterized for particle size and polydispersity index (PDI) revealed particle size were found to be between 57.08 nm 
to169.5 nm and PDI 0.252 to 0.639 respectively. The results signpost that stirring speed during ionic gelation reaction was also decisive 
parameters for the size of the nanoparticles obtained. Further characterization involved to show polymer-drug interaction was FTIR and DSC. 
This paper grants a revision of the physical factors elaborate in attaining nanoparticles in order to regulate the particle size of polymeric 
nanoparticles made from chitosan, without any surplus chemical treatment. 
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INTRODUCTION 
In modern age of chemotherapy, cancer is one of the leading 
causes of the death all over the world. Cancer is state in 
which normal growth controlling mechanisms of the cells are 
permanently impaired, permitting the progressive growth of 
cells without reaching growth equilibrium. Since cancer cells 
proliferate rapidly, they need augmented supply of nutrients 
and this leads to over expression of various receptors on the 
surface of these cells. A basic tenet of pharmaceutical 
formulation science is that the dosage form exists to 
optimize the delivery of a pharmaceutical active to its site of 
action in the most effective and safe manner1. 
Throughout previous epochs say 20 years, a generous 
amount of work has been conveyed on chitosan and its 
budding use in numerous bio applications. Chitosan is a 
linear polysaccharide composed of arbitrarily circulated β-
(1-4)-linked d-glucosamine and N-acetyl-d glucosamine. As 
compared to various organic polymer chitosan have inherent 
properties i.e. non-toxicity, biocompatibility, 
biodegradability, cationic properties, bio adhesive 
characteristics and permeability-enhancing properties. 
Chitosan-constructed particles have been comprehensively 
deliberate for delivery of anti-cancer agents, therapeutic 
proteins, genes, antigens, and so on2-7. Chitosan is the most 
appropriate for custom as a non-viral vector for gene 
delivery, particularly with reverence to transfection 
efficiency8-9. Consequently, variability existing in the initial 
chitosan will undoubtedly govern the features of the 
nanoparticles obtained.  
These nanoparticles can attain a size of up to 1000 nm and 
positive zeta potential of between +20 mV and +60 mV9-10 
Chitosan–tripolyphosphate nanoparticles are envisioned for 
in-vivo administration, so that no detrimental effects exists 
that may jeopardies the welfare of the organism to which 
they are brought. The ionic gelation technique encounters 
this requirement; meanwhile the method does not require 
the toting of any organic solvents, thus evading the 
problematic exclusion of filtrates prior to conveyance into 
living organism11. 
Breast cancer is the most common invasive cancer in women 
worldwide 12. In cancer treatment, nanotechnology grasps 
great promise to transfigure drug delivery, gene therapy, 
diagnostics and many areas of research, development and 
clinical application 13. In overall, nanocarriers may shield 
drug from degradation, enhance drug absorption by easing 
diffusion through epithelium, vary pharmacokinetic and 
tissue distribution profile, and/ or improve intracellular 
penetration. Also, Nano systems endured found valuable to 
improve the enactment of imaging techniques applied for the 
in vivo diagnosis of tumors 14. 
In recent years, a considerable work has been directed to the 
oral administration of anticancer drugs, on account of the 
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need to facilitate drug administration in patients treated for 
cancer using a more acceptable route. The expectations are 
to improve convenience and to reduce hospitalization where 
possible.15-16The use of colloidal preparations could modify 
the biopharmaceutical properties of the drug, such as 
solubility and permeability, without changing its chemical 
structure. 
A Nanoparticle is composed of atoms in either a single- or 
poly-crystalline arrangement having at least one dimension 
smaller than 100 nanometers17. Polymeric NPs have shown 
preferential accumulation at tumor sites, their usage as 
carriers improves efficacy and reduces side effects. Chitosan 
(CS) has been widely used to prepare nanoparticulate drug 
delivery system since has many good bio properties and 
physiochemical characteristics. CS is a natural 
polysaccharide which derived from chitin by deacetylation. 
This cationic polymer is regarded as biocompatible, 
biodegradable and non-toxic. The cationic properties of CS 
are particularly valuable for drug delivery systems. For 
example, ion complexes between CS and anionic drugs (i.e. 
methotrexate (MTX)) can be formed to NPs 18-20. 
Ionotropic gelation technique is based on the ionic 
interactions between the positively charged CH and the 
negatively charged groups of polyanions, such as sodium tri-
polyphosphate, which is the most extensively, used ion 
crosslinking due to its non-toxic and multivalent properties2. 
Sodium tri polyphosphate is the only water soluble inorganic 
polyphosphate able to spontaneously form nanoparticles by 
electrostatic interactions between the long polyphosphate 
chains and the CH22-25. 
Regarding the characteristic size range of chitosan 
nanoparticles, it is also of interest to analyses to what extent 
it is possible to obtain a higher percentage of a given particle 
size, depending on the mechanical parameters of the 
reaction. This information would contribute to defining a 
methodology for systematic and controlled production. 
In this study we proposed to prepare, optimize and evaluate 
methotrexate loaded chitosan nanoparticles for targeted 
delivery towards breast cancer cells. 
MATERIALS AND METHODS 
Materials:  
Methotrexate was received as gift sample from Khandelwal 
Laboratories Pvt. Ltd. Pune, India. Chitosan was obtained 
from Central Institute of Fisheries, Cochin; TPP and all other 
chemicals were AR grade and used as received.   
Preparation of carrier system:  
Chitosan nanoparticles were prepared according to a 
modified method of Calvo et al. 1996 12,26 with slight 
modifications based on the ionic gelation of chitosan with 
STPP anions. Chitosan (CH) solution (2mg/ml) was prepared 
by dissolving CH in acetic acid solution (1.5%) using 
magnetic stirrer (Aarson, India). Sodium tripolyphosphate 
solution (1mg/ml) was added drop wise to 4ml at the rate of 
1 ml/min to chitosan solution using syringe needle under 
vigorous magnetic stirring at room temperature. Sonicate 
the formulation for 15 minutes using sonicator (Digital 
Ultrasonic Cleaner, Jyoti Scientific, India), then disperse in 
water and separated by centrifugation (Rolex Centrifuge) for 
10 minutes.  
Various formulation and process variables i.e. weight ratio of 
chitosan and STPP, chitosan to enoxaparin weight ratio, 
stirring speed and stirring time, which affect 
characterization of nanoparticles, were optimized on the 
basis of their effect on drug entrapment efficiency and 
particle size. The various variables were optimized by 
varying one variable at a time and keeping other variables 
constant (Table 1). Based on an optimization procedure 
designed by us, a number of parameters were investigated 
by changing one parameter while keeping the others 
constant. The prepared nanoparticles were used for further 
studies. 
Characterization of nanoparticles 
Particle size and zeta potential determination: The 
average particle size and zeta potential of CS-NPs were 
determined by Photon correlation spectroscopy in a Zeta-
sizer (DTS version 4.10, Malvern Instruments, England). 
Poly-disparity index (PDI) was also measured to determine 
particle size distribution.  
Shape and Surface Morphology: Shape and surface 
morphology of nanoparticles was determined by scanning 
electron microscopy (SEM). For SEM, samples were 
examined under a scanning electron microscope (LEO 435 
VP, Eindhoven Netherlands) at an acceleration voltage of 30 
kV, and photomicrographs were taken at 2890X.  
Fourier transform infrared spectroscopy study: The FTIR 
spectral measurement were carried out on a Perkin Elmer 
Spectrum 21- prestige spectrophotometer. The by triturating 
3-5 mg of drug with polymer samples with 100-150 mg of 
KBr and compressed on a hydraulic press to make pellets.  
Spectra were taken by scanning the samples. The observed 
peaks were compared with those standard FTIR spectra. 
Indian Pharmacopoeia, 2010). 
Differential Scanning Calorimetry study: DSC is a thermo-
analytical technique used to observe fusion and 
crystallization events. Thermograms were obtained in a 
Shimadzu DSC-50 system (Shimadzu, Kyoto, Japan). 5 mg of 
lyophilized powder sample was placed in a standard 
aluminum pan and heated from 0 to 350 ◦C at a heating 
constant rate of 10 ◦C/min under constant purging of 
nitrogen at 20 mL/min.  
RESULTS AND DISCUSSION 
Preparation and optimization:  
The characteristics of the chitosan/TPP particles prepared 
with different concentrations of chitosan or TPP were 
studied. The results indicated that the particle size increased 
with increasing the concentration of either chitosan or TPP. 
Calvo et al. found that the formation of chitosan/TPP 
nanoparticles was only possible for some specific 
concentrations of chitosan and TPP. This fact was also 
verified in our study that in order to avoid the formation of 
any micro-particles, the concentration of chitosan or TPP 
needed to be below 1.5 mg/mL and 1.0 mg/mL, respectively. 
In these concentration ranges, it seemed that the 
concentration of chitosan or TPP had little effect on the 
monodispersity of the nanoparticles, since their PDI values 
were all below 0.05. Results of optimization were illustrated 
in Table 1. 
It is known that under acidic conditions, there is electrostatic 
repulsion between chitosan molecules due to the protonated 
amino groups of chitosan, meanwhile, there also exist inter 
chain hydrogen bonding interactions between chitosan 
molecules. Below a certain concentration of chitosan (2.0 
mg/mL as reported), the intermolecular hydrogen bonding 
attraction and the intermolecular electrostatic repulsion are 
in equilibrium27-29. Therefore, in this concentration range, as 
chitosan concentration increases, chitosan molecules 
approach each other with a limit, leading to a limited 
increase in intermolecular cross-linking, thus larger but still 
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nanoscale particles are formed. Above this concentration, 
microparticles are easily formed probably due to the 
stronger hydrogen bonding interactions leading to plenty of 
chitosan molecules involved in the cross-linking of a single 
particle. The formation of micro-particles usually leads to a 
flocculent precipitate due to the electrostatic repulsion 
between particles are not sufficient to maintain the stability 
of these large particles. 
It was also found that chitosan at low concentration could 
form stable nanoparticles even at a low mass ratio of 
chitosan to TPP, while chitosan at higher concentration could 
only form stable nanoparticles at a higher mass ratio of 
chitosan to TPP. For example, when the concentration of TPP 
was fixed at 0.5 mg/mL, a chitosan concentration of 0.5 
mg/mL could form stable nanoparticles, while a chitosan 
concentration of 1.0 mg/mL would form aggregates. To 
explain this phenomenon, it is inferred that as chitosan 
concentration decreases, the intermolecular distance 
increases, thus leading to a decrease in intermolecular cross-
linking between chitosan molecules while an increase in 
cross-linking density between chitosan and TPP, namely an 
increase in the ratio of moles of TPP to the moles of chitosan 
repeating units30.This can be utilized to prepare 
chitosan/TPP nanoparticles with smaller size, since an 
appropriate increase in the mass ratio is conducive to reduce 
the particle size. 
Characterization of carrier system:  
The optimized nanoparticles were characterized for particle 
size and polydispersity index (PDI) using Zetasizer Nano 
ZS90 (Malvern Instruments, Malvern, UK) showed particle 
size and PDI between 57.08 nm to169.5 nm and 0.252 to 
0.639 respectively (Fig 2). The results indicate that stirring 
speed during ionic gelation reaction is decisive for the size of 
the nanoparticles obtained. 
Shape and surface morphology: 
Prepared chitosan and alginate coated chitosan 
nanoparticles were characterized for shape and surface 
morphology, particle size, drug entrapment efficiency, zeta 
potential and polymer-polymer interaction. The shape and 
surface morphology of carrier system were characterized by 
SEM photomicrographs (Fig. 1). Nanoparticles were found to 
be spherical in shape but the surface of chitosan 
nanoparticles was found to be smooth. 
FTIR Analysis:  
Drug excipient interaction study was one of the important 
parameters which depict much information regarding the 
stability of formulations, drug release from them27.The FTIR 
spectral measurement were carried out on a Perkin Elmer 
Spectrophotometer. In order to examine the interaction 
between components of nanoparticulate systems, 
preliminary concerns were taken over comparative FTIR 
spectrum of drug MTX, chitosan, TPP and physical mixture of 
drug with chitosan and TPP shown in Fig 3. In MTX IR 
spectrum, peak at 3406 cm-1 corresponds to –OH group and 
1600 cm-1 corresponds to C=O band and the spectrum is 
comparable to that of earlier study. As shown in Fig.3 
specific MTX peaks were observed in physical mixture. 
Differential Scanning Calorimetry (DSC):  
Drug excipient interaction study is used to get information 
about both the physical and the energetic properties of a 
compound. DSC is very useful for the investigation of the 
thermal properties of drug delivery carriers, providing both 
qualitative and quantitative information about the 
physiochemical state of drug inside the drug delivery 
system26 .There is detectable endotherm when the drug is 
present in molecular dispersion or solid solution in the 
polymeric system loaded with drug.27 
 
Table 1: Data represents stirring time v/s particle size and polydispersity index (PDI) of different optimized 
formulations. 
Formulation Code Stirring Time (hrs) Particle size (nm) PDI  
R1S1 0.5 194.33±8.1 0.519±0.021 
R2S2 1.0 84.30±3.3 0.254±0.011 
R3S3 1.5 56.37±2.4 0.212±0.009 
R4S4 2.0 91.4±4.4 0.250±0.013 
R5S5 2.5 168.1±9.2 0.637±0.021 
n=3 values are expressed Mean ±SD. 
 
Figure 1: Photomicrograph of chitosan nanoparticles by SEM analysis. 
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Figure 2: particle size distribution of chitosan nanoparticles 
 
Figure 3: FTIR spectra of MTX, CS, TPP and physical mixture of MTX,CS and TPP 
 
CONCLUSION 
Chitosan anchored nanoparticles of MTX were prepared by 
ionotropic gelation method. The polymeric particles in a 
nanosize range with a desired drug polymer ratio can be 
obtained. It may be a potential alternative dosage form of the 
drug for the treatment of breast cancer. 
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